ALK and non-small cell lung carcinoma: The first-generation ALK-TKI, crizotinib, was the first ALK inhibitor approved for the treatment of patients with metastatic ALK-positive NSCLC, which can induce ALK, c-MET, and ROS-1 fusion protein inhibition [39].